The production of cast recipient blocks for paraffin tissue microarrays using conventional steel embedding moulds

Vogel, Ulrich

doi:10.1111/j.1365-2559.2009.03384.x

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In each patient, four localizations were included in the TMA: (A) tissue from the tumor center, (B) the malignant border of the tumor, (C) benign tissue adjacent to the tumor, and (D) tumor-distant benign prostatic tissue (Figure 1). The process was performed as previously reported [11, 12].…”

Section: Methodsmentioning

confidence: 99%

Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer

et al. 2019

View full text Add to dashboard Cite

The aim of this study was to evaluate the expression of mammalian target of rapamycin (mTOR), phosphorylated-mTOR (p-mTOR), and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) in prostate cancer (PCa) in order to assess intratumoral heterogeneity and correlation with clinicopathological parameters. Tissue samples from 115 patients undergoing radical prostatectomy were included in a tissue microarray comprising (A) tissue from the tumor center, (B) malignant border of the tumor, (C) tumor-adjacent benign tissue, and (D) tumor-distant benign prostatic tissue. Immune reactive scores 0-12 were correlated with clinical data in reference to localization. A meta-analysis of studies investigating the association between biochemical recurrence (BCR) and parameters of the mTOR pathway was conducted. Regardless of the location within the tumor, cancer tissue showed higher expression of mTOR, p-mTOR, and 4EB-P1 compared to benign tissue (p < 0.01). Significant differences in expression between tissue samples from groups C and D were observed for mTOR and p-mTOR. When considering expression according to the pathological stage, we observed lower p-mTOR expression in pT3 vs. pT2 (7.9 and 6.3; p = 0.01). After a median follow-up of 74.5 months (IQR 65.0-84.0), 27 patients (23.47%) developed BCR. Weak staining of mTOR was associated with shorter time to BCR (HR: 2.0; p = 0.049) after correcting for PSA and T stage. However, a significant association of mTOR expression with BCR was found for specimens from the malignant border of the tumor (B) but not the tumor center (A) (p = 0.0034 log rank). In a meta-analysis, we found that the expressions of mTOR ((RR) = 0.70; 95% CI 0.43-1.12; p = 0.13) and 4E-BP1 ((RR) = 0.86; p = 0.53) were not statistically associated with BCR, while strong staining of p-mTOR was associated with a lower risk of BCR ((RR) = 0.57; p = 0.002). All 3 markers showed stronger expression in PCa and exhibited local gradients in relation to the border of tumor and healthy tissue. Our results suggest an important role of intratumor heterogeneity for the use of mTOR parameters as biomarkers in PCa.

show abstract

Section: Methodsmentioning

confidence: 99%

Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Another modification of this technique was introduced by Vogel as top pin tissue arrayer which can be used with ordinary steel embedding molds to cast the holes of the recipient block (Figure 6E,F) [54]. …”

Section: The Development Of the Tmas In The Course Of Timementioning

confidence: 99%

Overview on Techniques to Construct Tissue Arrays with Special Emphasis on Tissue Microarrays

Vogel

2014

Microarrays

View full text Add to dashboard Cite

With the advent of new histopathological staining techniques (histochemistry, immunohistochemistry, in situ hybridization) and the discovery of thousands of new genes, mRNA, and proteins by molecular biology, the need grew for a technique to compare many different cells or tissues on one slide in a cost effective manner and with the possibility to easily track the identity of each specimen: the tissue array (TA). Basically, a TA consists of at least two different specimens per slide. TAs differ in the kind of specimens, the number of specimens installed, the dimension of the specimens, the arrangement of the specimens, the embedding medium, the technique to prepare the specimens to be installed, and the technique to construct the TA itself. A TA can be constructed by arranging the tissue specimens in a mold and subsequently pouring the mold with the embedding medium of choice. In contrast, preformed so-called recipient blocks consisting of the embedding medium of choice have punched, drilled, or poured holes of different diameters and distances in which the cells or tissue biopsies will be deployed manually, semi-automatically, or automatically. The costs of constructing a TA differ from a few to thousands of Euros depending on the technique/equipment used. Remarkably high quality TAs can be also achieved by low cost techniques.

show abstract

XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence

et al. 2011

View full text Add to dashboard Cite

show abstract

The production of cast recipient blocks for paraffin tissue microarrays using conventional steel embedding moulds

Cited by 3 publications

References 9 publications

Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer

Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer

Overview on Techniques to Construct Tissue Arrays with Special Emphasis on Tissue Microarrays

XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence

Contact Info

Product

Resources

About